A palmitoylated pentapeptide (Pal-KTTKS) that is one of the most commercially successful cosmetic peptides. It mimics a collagen fragment that signals fibroblasts to produce new collagen. Found in thousands of anti-aging skincare products worldwide.
Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS) is a lipopeptide consisting of the pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser) conjugated to palmitic acid (C16 fatty acid) for skin penetration. Developed by Sederma (now part of Croda), it was introduced in 2000 and quickly became one of the most widely used anti-aging peptides in cosmetics.
The KTTKS sequence is a fragment of collagen type I pro-peptide. When collagen is degraded (as in aging or UV damage), these fragments are released and act as matrikines — signaling molecules that tell fibroblasts 'collagen has been broken down, make more.' Matrixyl mimics this natural signal.
Matrixyl (palmitoyl pentapeptide-4, or Pal-KTTKS) was one of the first peptides to achieve widespread commercial success in the skincare industry. Developed by Sederma, Matrixyl works by mimicking a collagen fragment — the pentapeptide KTTKS is a sequence found in type I collagen that, when recognized by fibroblast receptors, signals the skin to produce more collagen. The palmitoyl (palmitic acid) lipid tail enhances skin penetration by increasing the peptide's lipophilicity, allowing it to cross the stratum corneum more effectively than the unmodified peptide.
Clinical studies have demonstrated that topical Matrixyl application produces measurable improvements in wrinkle depth, skin roughness, and skin thickness compared to vehicle control. These effects are modest compared to retinoids or injectable treatments, but Matrixyl is well-tolerated and does not cause the irritation, photosensitivity, or peeling associated with retinoids — making it suitable for sensitive skin types and as a complementary ingredient in anti-aging formulations.
Matrixyl has spawned a family of related peptides including Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7), Matrixyl Synthe'6 (palmitoyl tripeptide-38), and Matrixyl Morphomics — each targeting different aspects of skin aging. For a comprehensive overview of peptide skincare ingredients, see our skincare peptides guide.
Matrixyl signals through the matrikine pathway. When collagen is degraded by matrix metalloproteinases (MMPs), specific fragments like KTTKS are released. These fragments bind to cell surface receptors on fibroblasts, triggering TGF-β signaling and stimulating new extracellular matrix protein production. By applying synthetic KTTKS, Matrixyl mimics this degradation signal without actual collagen damage, tricking fibroblasts into producing new collagen.
| Pathway | Effect | Significance |
|---|---|---|
| Matrikine signaling | KTTKS fragment activates fibroblast collagen production | Mimics natural collagen turnover signal |
| Collagen I/III synthesis | Upregulates procollagen gene expression | Increases dermal collagen density and skin thickness |
| Fibronectin stimulation | Increases fibronectin production | Improves extracellular matrix organization |
| MMP modulation | May reduce excessive MMP activity | Slows collagen degradation while promoting synthesis |
| Palmitoyl delivery | C16 fatty acid enables skin penetration | Crosses stratum corneum to reach dermal fibroblasts |
| Study | Design | Findings | Level |
|---|---|---|---|
| Wrinkle reduction | Double-blind, n=93, 12 weeks | Matrixyl cream reduced wrinkle depth and volume by up to 68% vs placebo (Sederma study) | Level II |
| Collagen synthesis | In vitro, fibroblast culture | Pal-KTTKS increased collagen types I, III, and IV production in a dose-dependent manner | Preclinical |
| Comparison to retinol | Split-face study | Matrixyl showed comparable wrinkle reduction to retinol with less irritation | Level II-III |
| Skin thickness | Clinical study with ultrasound | Increased dermal thickness after 4 months of topical application | Level II |
Excellent topical safety: Matrixyl has been used in consumer skincare products for over two decades with an excellent safety record. No significant adverse effects have been reported in clinical studies or post-market surveillance. Skin irritation, allergy, and sensitization rates are extremely low.
Suitable for sensitive skin: Unlike retinoids (which cause peeling, redness, and photosensitivity) and vitamin C (which can be irritating at high concentrations), Matrixyl is well-tolerated by virtually all skin types, including sensitive and rosacea-prone skin.
Stability: The palmitoyl modification improves stability compared to the unmodified KTTKS peptide. However, like all peptide actives, Matrixyl can degrade in formulations with extreme pH, high temperatures, or incompatible co-ingredients. Properly formulated products at appropriate pH (4.5-6.0) maintain peptide stability.
| Jurisdiction | Status |
|---|---|
| FDA | Not regulated as a drug. Classified as a cosmetic ingredient. |
| EU | Listed in CosIng database as approved cosmetic ingredient |
| INCI name | Palmitoyl Pentapeptide-4 |
| Market | Found in thousands of skincare products from mass-market to luxury |